Literature DB >> 23494586

Factors associated with a better therapeutic effect of solifenacin in patients with overactive bladder syndrome.

Sheng-Mou Hsiao1, Ho-Hsiung Lin, Hann-Chorng Kuo.   

Abstract

AIMS: To analyze the predictors of therapeutic success after solifenacin treatment.
METHODS: Between January 2008 and December 2011, all patients with overactive bladder syndrome (OAB) who consecutively visited the urologic outpatient clinics of a medical center were prospectively enrolled. All enrolled patients received 5 mg solifenacin once a day for 12 weeks.
RESULTS: Overall, 648 patients, 332 men, and 316 women, completed the 12-week study. The overall success rate was 48.8%. The success rate for female patients was superior to that for male patients (55.4% vs. 42.5%, P <  .001). The urgency severity scale (USS) score, daytime frequency, nocturia, voided volume, and bladder capacity were all improved after 12 weeks' treatment. Multivariate logistic regression analysis revealed that female gender, high USS score, high maximum flow rate (Qmax ), and low postvoid residual volume (PVR) were all significant predictive factors for success after antimuscarinic treatment. USS score = 4 and Qmax ≥ 12 ml/sec were the most strongly predictive cutoff values for success, with receiver operating characteristic curve (ROC) areas of 0.70 (sensitivity = 66.8%, specificity = 66.0%) and 0.63 (sensitivity = 80.7%, specificity = 43.1%), respectively. PVR ≥ 70 ml was the most predictive cutoff value for failure, with a ROC area of 0.58 (sensitivity = 18.2%, specificity = 93.7%).
CONCLUSIONS: Female gender, high USS score, high Qmax , and low PVR were associated with better therapeutic efficacy. These findings could serve as an initial guide or assist in consultation regarding the treatment of OAB patients with antimuscarinics.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  antimuscarinics; overactive bladder syndrome; urgency

Mesh:

Substances:

Year:  2013        PMID: 23494586     DOI: 10.1002/nau.22394

Source DB:  PubMed          Journal:  Neurourol Urodyn        ISSN: 0733-2467            Impact factor:   2.696


  8 in total

1.  Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR Trial.

Authors:  David Staskin; Jeffrey Frankel; Susann Varano; Michael Kennelly; Diane K Newman; Matt T Rosenberg; Denise D Shortino; Rachael A Jankowich; Paul N Mudd
Journal:  Int J Clin Pract       Date:  2022-04-13       Impact factor: 3.149

2.  Association of baseline severity of lower urinary tract symptoms with the success conservative therapy for urinary incontinence in women.

Authors:  Aneta Obloza; Roderick Teo; Emily Marriott; Gillian Parker; Douglas Tincello
Journal:  Int Urogynecol J       Date:  2018-10-10       Impact factor: 2.894

3.  Duration of Antimuscarinic Administration for Treatment of Overactive Bladder Before Which One Can Assess Efficacy: An Analysis of Predictive Factors.

Authors:  Sheng-Mou Hsiao; Chun-Hou Liao; Ho-Hsiung Lin; Hann-Chorng Kuo
Journal:  Int Neurourol J       Date:  2015-09-22       Impact factor: 2.835

4.  Post-Irradiation Bladder Syndrome After Radiotherapy of Malignant Neoplasm of Small Pelvis Organs: An Observational, Non-Interventional Clinical Study Assessing VESIcare®/Solifenacin Treatment Results.

Authors:  Janusz Jaszczyński; Zbigniew Kojs; Andrzej Stelmach; Łukasz Wohadło; Elzbieta Łuczyńska; Sylwia Heinze; Janusz Rys; Jerzy Jakubowicz; Piotr Chłosta
Journal:  Med Sci Monit       Date:  2016-07-30

Review 5.  Recent research on the role of urodynamic study in the diagnosis and treatment of male lower urinary tract symptoms and urinary incontinence.

Authors:  Yuan-Hong Jiang; Hann-Chorng Kuo
Journal:  Ci Ji Yi Xue Za Zhi       Date:  2017 Apr-Jun

6.  Evaluation of the relationship of cholinergic metabolites in urine and urgency urinary incontinence.

Authors:  David Sheyn; Sara Myers; Dominique Tucker; Fred E Hazlett; Xiaolin Li; Britt Conroy; Adonis K Hijaz
Journal:  Int Urogynecol J       Date:  2021-04-05       Impact factor: 1.932

7.  Efficacy and Safety of Intravesical OnabotulinumtoxinA Injection in Patients with Detrusor Hyperactivity and Impaired Contractility.

Authors:  Chung-Cheng Wang; Cheng-Ling Lee; Hann-Chorng Kuo
Journal:  Toxins (Basel)       Date:  2016-03-18       Impact factor: 4.546

8.  Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome.

Authors:  Sheng-Mou Hsiao; Ho-Hsiung Lin; Hann-Chorng Kuo
Journal:  PLoS One       Date:  2016-01-29       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.